Latest: AVM Biotechnology was just interviewed by Seattle’s KOMO 4 News about our COVID-19 treatment, AVM0703, that could be better than Oxford’s released trial results. Watch now!

AVM0703 could be the first choice for terminal, no-option cancer

Pharmacology
Cancer Models
Approval Process

Personal Mission

AVM0703 has FDA approval to proceed with clinical trials in R/R Non-Hodgkins Lymphoma